Current and historical daily PE Ratio for ME Therapeutics Holding Inc (
XCNQ:METX
) from 2023 to Jun 14 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. ME Therapeutics Holding stock (XCNQ:METX) PE ratio as of Jun 14 2024 is 0.
More Details
ME Therapeutics Holding Inc (XCNQ:METX) PE Ratio (TTM) Chart
ME Therapeutics Holding Inc (XCNQ:METX) PE Ratio (TTM) Historical Data
View and export this data going back to 2023. Start your Free Trial
Total 141
- 1
- 2
ME Therapeutics Holding PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-14 | At Loss | 2024-04-12 | At Loss |
2024-06-13 | At Loss | 2024-04-11 | At Loss |
2024-06-12 | At Loss | 2024-04-10 | At Loss |
2024-06-11 | At Loss | 2024-04-09 | At Loss |
2024-06-10 | At Loss | 2024-04-08 | At Loss |
2024-06-07 | At Loss | 2024-04-05 | At Loss |
2024-06-06 | At Loss | 2024-04-04 | At Loss |
2024-06-05 | At Loss | 2024-04-03 | At Loss |
2024-06-04 | At Loss | 2024-04-02 | At Loss |
2024-06-03 | At Loss | 2024-04-01 | At Loss |
2024-05-31 | At Loss | 2024-03-29 | At Loss |
2024-05-30 | At Loss | 2024-03-28 | At Loss |
2024-05-29 | At Loss | 2024-03-27 | At Loss |
2024-05-28 | At Loss | 2024-03-26 | At Loss |
2024-05-27 | At Loss | 2024-03-25 | At Loss |
2024-05-24 | At Loss | 2024-03-22 | At Loss |
2024-05-23 | At Loss | 2024-03-21 | At Loss |
2024-05-22 | At Loss | 2024-03-20 | At Loss |
2024-05-21 | At Loss | 2024-03-19 | At Loss |
2024-05-20 | At Loss | 2024-03-18 | At Loss |
2024-05-17 | At Loss | 2024-03-15 | At Loss |
2024-05-16 | At Loss | 2024-03-14 | At Loss |
2024-05-15 | At Loss | 2024-03-13 | At Loss |
2024-05-14 | At Loss | 2024-03-12 | At Loss |
2024-05-13 | At Loss | 2024-03-11 | At Loss |
2024-05-10 | At Loss | 2024-03-08 | At Loss |
2024-05-09 | At Loss | 2024-03-07 | At Loss |
2024-05-08 | At Loss | 2024-03-06 | At Loss |
2024-05-07 | At Loss | 2024-03-05 | At Loss |
2024-05-06 | At Loss | 2024-03-04 | At Loss |
2024-05-03 | At Loss | 2024-03-01 | At Loss |
2024-05-02 | At Loss | 2024-02-29 | At Loss |
2024-05-01 | At Loss | 2024-02-28 | At Loss |
2024-04-30 | At Loss | 2024-02-27 | At Loss |
2024-04-29 | At Loss | 2024-02-26 | At Loss |
2024-04-26 | At Loss | 2024-02-23 | At Loss |
2024-04-25 | At Loss | 2024-02-22 | At Loss |
2024-04-24 | At Loss | 2024-02-21 | At Loss |
2024-04-23 | At Loss | 2024-02-20 | At Loss |
2024-04-22 | At Loss | 2024-02-19 | At Loss |
2024-04-19 | At Loss | 2024-02-16 | At Loss |
2024-04-18 | At Loss | 2024-02-15 | At Loss |
2024-04-17 | At Loss | 2024-02-14 | At Loss |
2024-04-16 | At Loss | 2024-02-13 | At Loss |
2024-04-15 | At Loss | 2024-02-12 | At Loss |
ME Therapeutics Holding Inc (XCNQ:METX) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
ME Therapeutics Holding Inc
NAICS : 541714
SIC : 3741
ISIN : CA5527671054
Description
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.